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ABSTRACT 
Background: Gastroesophageal reflux disease (GERD) is a chronic disorder, 
and although effective short-term treatment s rategies are known, the rate of re- 
lapse within 1 year is as high as 90% despite successful acute treatment. Con- 
sequently, most patients with GERD require an effective long-term management 
strategy to achieve adequate symptom control and maintain mucosal healing. 
Objective: The present study was undertaken to compare the control of 
GERD symptoms during long-term (24-week) treatment with pantoprazole 
20 mg used on-demand or continuously in patients with mild GERD after com- 
plete relief of acute GERD symptoms. 
Methods: Patients with endoscopically confirmed Savary/Miller grade 0 
(normal mucosa) or I (patchy red lesions without white coating or with central 
white coating) GERD were enrolled in this multinational, multicenter study com- 
prising 2 phases. In the first phase, which was open label, patients were treated 
with pantoprazole 20 mg QD for 4 weeks. The presence and intensity of the symp- 
toms of heartburn, acid regurgitation, and pain on swallowing were assessed. 
In the second phase, which was an open-label, 24-week, randomized esign, 
only patients completely free of GERD symptoms after acute treatment were 
included. During this phase, on-demand treatment with pantoprazole 20 mg was 
directly compared with continuous treatment. The rate of failure to control 
GERD symptoms after 24 weeks of treatment was estimated using the Kaplan- 
Meier method. Subsequently, the difference between treatments (on-demand 
minus continuous) and its 95% CI were calculated, and the on-demand treat- 
ment was tested for noninferiority using a predefined noninferiority margin of 
20%. The mean daily symptom loads were compared between the treatment 
groups using the 1-sided Wilcoxon rank sum test on a 5% oL level. The point esti- 
mate of the difference was determined using the Hodges-Lehman estimator and 
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the 1-sided 95% CI according to Moses. The number of patients unwilling to 
continue due to insufficient control of heartburn, acid regurgitation, and pain 
on swallowing was analyzed using the Kaplan-Meier (time-to-event) analysis. 
Analysis was performed in the same manner as for the rate of failure to control 
GERD symptoms, but the 95% CI was interpreted for statistical superiority. 
Results: A total of 558 patients were enrolled in this study. At the end of the 
acute phase, 82.1% of patients in the per-protocol (PP) population and 79.1% in 
the intent-to-treat (ITT) population were relieved of all GERD symptoms, and 
subsequently entered the long-term phase. After 24 weeks of treatment, analy- 
sis of the failure rates revealed that on-demand treatment was noninferior to 
continuous treatment because the 95% CI was completely below 20% (ITT, 
12.1% difference [95% CI, -~ to 18.9%]; PP, 10.1% difference [95% CI, -~ to 
17.7%]). The higher perceived mean (SD) daily symptom load in the on-demand 
group (ITT, 1.26 [1.49] vs 0.82 [1.34]) was balanced by the reduced tablet intake 
in that group (PP, 0.51 [0.31] vs 0.97 [0.11] tablets/d; P< 0.001). With respect o 
the rate of patients unwilling to continue treatment, no statistically significant 
difference was observed between the on-demand and continuous groups (ITT/ 
PP, 0.95/1.13 vs 0.95/1.26). 
Conclusions: In this study of pantoprazole 20 mg tablets in patients with 
mild GERD, patients receiving on-demand treatment benefited despite their 
higher symptom load. The similar rates of unwillingness to continue treatment 
in both groups might suggest hat patients were satisfied with the on-demand 
treatment strategy. On-demand treatment with pantoprazole 20 mg was found 
to be noninferior compared with continuous therapy with regard to symptom 
control. Both on-demand and continuous treatments were well tolerated. (Curt 
Ther Res Clin Exp. 2005;66:345-363) Copyright © 2005 Excerpta Medica, Inc. 
Key words: drug administration schedule, follow-up study, gastroesophageal 
reflux/drug therapy, heartburn, long-term care, treatment outcome, pantopra- 
zole, continuous, on-demand, as needed. 
INTRODUCTION 
Gastroesophageal reflux disease (GERD) is a chronic disorder, and although 
effective short-term treatment strategies are known, the rate of relapse within 
1 year is as high as 90% despite successful acute treatment. 1 Consequently, most 
patients with GERD, irrespective of whether the underlying disease was initially 
mild or severe, require an effective long-term management s rategy to achieve 
adequate symptom control and maintain mucosal healing. 1
Traditionally, long-term management s rategies have included daily mainte- 
nance treatment with proton pump inhibitors (PPIs) in low doses to maintain 
remission. However, recent studies 2-1° investigating PPIs used on-demand (1 dose 
on recurrence of symptoms, continued until symptom relief) showed that PPIs 
were more effective in preventing symptom relapse in nonerosive or mild GERD 
compared with placebo. These findings suggest hat for the long-term manage- 
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ment of mild GERD (after acute symptom relief), on-demand PPI therapy might 
be more effective compared with step-down treatments, uch as ranitidine or a 
motility agent. Galmiche et al u investigated the on-demand use of H2-receptor 
antagonists. Although the improvement was statistically significant compared 
with placebo, a 40% success rate is not encouraging. In an uncontrolled trial, 
Wilhelmsen et a112 reported better results with H2-receptor antagonists used 
on-demand, with 84% of patients reporting satisfaction with the therapy. En- 
couraged by these findings, Bytzer and Blum 13 developed algorithms for clini- 
cal practice. The on-demand modality evolved from patient habits. Intake 
behavior and compliance studies have shown that patients with GERD symp- 
toms generally do not use their medication as prescribed but only when their 
symptoms require treatment. ~4 Symptom-triggered use might give patients a 
sense of self-empowerment over their disease state. ~4 In addition to the ex- 
pected improvement in patients' willingness to continue treatment, the on- 
demand approach would seem to have the potential to substantially ower drug 
acquisition costs. 15J6 The use of on-demand PPI therapy might avoid the costs 
of switching to a PPI due to failure with an H2-blocker or a motility agent. 
Several ong-term studies of up to 1-year duration with continuous pantopra- 
zole 20 mg QD demonstrated maintenance of healing of erosive esophagitis, 
sustained symptom relief, and statistical superiority to placebo. ~7-~9 Further- 
more, recent studies 2°,2~ of pantoprazole 20 mg on-demand in patients with non- 
erosive or mild GERD (grade 0 [normal mucosa] or I [patchy red lesions with- 
out white coating or with central white coating] according to Savary and 
Miller, 22 as modified by Siewert et a123) demonstrated that this treatment modal- 
ity was more effective in maintaining control of the 3 major GERD symptoms--  
heartburn, acid regurgitation, and pain on swallowing--and other GERD 
symptoms compared with placebo, and was well tolerated. However, based on 
an unstructured MEDLINE search, fully published data from a direct compari- 
son of on-demand versus maintenance treatment with pantoprazole are lacking. 
Hence, the present study was undertaken to compare the control of GERD 
symptoms during long-term (24-week) treatment with pantoprazole 20 mg used 
on-demand or continuously in patients with mild GERD after complete relief of 
acute GERD symptoms. 
PATIENTS AND METHODS 
Design, Conduct, and Ethical Considerations 
This multicenter study was conducted in 2 phases and involved 58 active cen- 
ters: 29 in Germany, 12 in France, 11 in Switzerland, and 6 in Hungary. The first, 
acute phase was conducted as an open-label symptom-relief study. Patients aged 
18 to 75 years who had endoscopically confirmed Savary/Miller 22,23 grade 0 or I 
GERD and who experienced frequent episodes of at least one of the characteris- 
tic GERD symptoms (heartburn, acid regurgitation, and/or pain on swallowing) 
during the previous 3 months were eligible for inclusion. At least one of the 
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symptoms had to be of at least moderate intensity on the last 3 days prior to 
inclusion. 
In this acute phase, pantoprazole 20 mg QD was administered for 4 weeks. For 
the evaluation of symptoms, patients recorded the presence and intensity of the 
symptoms of heartburn, acid regurgitation, and pain on swallowing in a patient 
diary on a daily basis. During the baseline visit and each follow-up visit, patients 
were asked about he intensity of heartburn, acid regurgitation, pain on swallow- 
ing, and 3 other symptoms (epigastric pain, abdominal pain, and retrosternal 
feeling of tightness) by the investigator. At the baseline visit, a complete medical 
history was documented, including demographic data, previous treatments for 
GERD symptoms, completed treatments for any other diseases, recent concomi- 
tant medication, and clinical symptoms. For tolerability assessment, a physical 
examination was performed at the final visit, and blood, serum, and urine sam- 
ples were analyzed at the first and final follow-up visits. 
Patients who were completely free of heartburn, acid regurgitation, and pain 
on swallowing and whose other symptoms (epigastric pain, abdominal pain, 
retrosternal feeling of tightness) were at most mild in severity for at least 3 con- 
secutive days prior to the first follow-up visit (after 4 weeks) entered the long- 
term phase of the study. This phase was performed as an open-label, random- 
ized, parallel-group comparison of on-demand and continuous treatment for 
6 months (24 weeks), with patients receiving either on-demand pantoprazole 
20 mg QD or continuous pantoprazole 20 mg QD. Randomization was performed 
using a computer-generated list. The study medication was packed in a sealed 
box and allocated according to the numbering in ascending order. The patient 
and the investigator first learned to which treatment group the patient was 
assigned when the patient opened the box. Patients in the on-demand group 
were asked to use the medication only if at least one of the characterisic GERD 
symptoms required treatment, with a maximum of 1 tablet/d; those in the con- 
tinuous group were instructed to receive 1 tablet of pantoprazole 20 mg QD. 
Each patient was scheduled for a total of 4 visits--the visit at the beginning of 
the study and 3 follow-up visits at 4, 16, and 28 weeks after the start of the study. 
To help calculate the mean symptom load (described later), all unused medica- 
tion was counted and documented by the investigator on the case-report form at 
each follow-up visit. 
For both phases, patients were excluded if they met any of the following cri- 
teria: the presence of any other gastrointestinal diseases (eg, endoscopically 
confirmed Savary/Miller grades II to IV GERD); florid peptic ulcer; known his- 
tory of Zollinger-Ellison syndrome, pyloric stenosis, ulcer complications, or 
gastric surgery (except appendectomy, cholecystectomy, and polypectomy); or 
severe disease of any other body system. The use of Helicobacter pylori eradi- 
cation therapy, systemic glucocorticosteroids, NSAIDs (except aspirin up to 
150 mg/d), and supportive medication for the treatment of gastrointestinal com- 
plaints (eg, PPIs, H2-receptor antagonists, prokinetics, sucralfate) was prohib- 
ited throughout the study. 
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The study was conducted according to the Good Clinical Practice guideline 24 
and the Declaration of Helsinki and its amendments. 25 Independent local ethics 
committees in the respective countries approved the protocol. Before enroll- 
ment, all patients provided written informed consent o participate. 
Symptom Assessment 
Assessment by Patient Diary 
Patients were instructed to document the symptom intensity of the 3 GERD 
symptoms (heartburn, acid regurgitation, and pain on swallowing) each day, 
using a 4-point scale (0 = none; 1 = mild; 2 = moderate; and 3 = severe). 
Invest igator 's  Assessment  
At each visit, the investigator questioned the patient about he intensity of the 
symptoms of heartburn, acid regurgitation, and pain on swallowing, and 3 addi- 
tional symptoms (epigastric pain, abdominal pain, retrosternal feeling of tightness) 
during the prior 3 consecutive days. Analogous to the patient's diary, the intensity 
was assessed on a 4-point scale (0 = none; 1 = mild; 2 = moderate; and 3 = severe). 
Primary End Point 
In this study, 2 treatment modalities were directly compared--on-demand treat- 
ment (with a mean of <1 tablet/d) versus continuous treatment (with exactly 
1 tablet/d). Hence, the primary end point of the study was assessed only in the 
long-term phase. Our intention was to demonstrate that on-demand therapy could 
be used to sufficiently (ie, acceptable tothe patient) control heartburn, acid regur- 
gitation, and pain on swallowing. Thus, the primary variable in this study was the 
difference in the estimated rates of patients with uncontrolled heartburn, acid 
regurgitation, and pain on swallowing between the 2 treatment groups. The symp- 
toms (as assessed in the patient's diary) were considered controlled until the time 
of failure, which was defined as the first point at which one of the following events 
occurred: (1) GERD symptoms of at least moderate severity were present for 3 or 
more consecutive days despite medication (event ime = the first of these 3 days); 
(2) use of >1 tablet of study medication on >3 consecutive days (event ime = the 
first of these 3 days); or (3) premature withdrawal from the study due to lack of 
efficacy (event ime = the date of withdrawal). 
Secondary End Points 
At the end of the acute phase (after 4 weeks of treatment), the overall symp- 
tom relief rate (based on the investigator's a sessment) and the relief rates for 
each symptom were calculated by dividing the number of patients free of symp- 
toms by the number of patients with symptoms at baseline. 
A secondary variable assessed for the long-term phase was the perceived 
mean daily symptom load, which combined information about symptoms (as 
assessed in the patient's diary) and medication intake. Using the symptom in- 
tensity of the 3 GERD symptoms (heartburn, acid regurgitation, and pain on 
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swallowing), a sum score  was calculated (range, 0-9) for each day of treatment. 
Because this sum score reflected only a selective status of the patient's GERD 
symptoms (ie, for a single point in time), an overall measure of the patient's 
symptoms was more appropriate and was done by adding the sum scores of all 
days and dividing that sum by the number of days that the patient participated 
in the study. In practice, we used the area under the overall sum score of symp- 
toms curve over the individual study time (AUC). The calculation of the AUC for 
a defined time period is commonly used to transfer a time-dependent function 
to a single value. Because the intake of study medication could vary greatly in 
the on-demand treatment group, medication i take was included in the calcula- 
tion of the perceived mean daily symptom load. Thus, the number of tablets of 
study medication used was divided by the individual study time, and this ratio 
was multiplied by the AUC. Because patients in the on-demand group, in the 
most extreme cases, might not have used any study medication (0), a weighting 
factor of 1 was added to ensure meaningful results. The perceived mean daily 
symptom load could range from 0 to 18 (maximum symptom load). 
Tolerability 
Adverse events (AEs) were documented ateach follow-up visit. The investi- 
gator assessed AEs using laboratory analysis, spontaneous reporting, and open 
questioning, and classified the causal relationship to the study medication as 
unrelated, unlikely to be related, likely to be related, or definitely related. The 
severity of AEs was graded as mild, moderate, or severe. 
Statistical Analysis 
The sample size was determined using nQuery Advisor version 4.0 
(Statistical Solutions, Saugus, Massachusetts). We assumed a failure rate to con- 
trol GERD symptoms after 24 weeks of treatment of 20% for continuous treat- 
ment and at most 27.5% for on-demand treatment. Although it is common to 
select as delta the proportion of the difference between an active treatment and 
placebo, when comparing 2 regimens of the same treatment, as was done in the 
present study, delta can be larger, especially if it is unclear how often patients 
in the on-demand group would use their medication; thus, we defined a nonin- 
feriority margin of 20%. With these values, we calculated that 300 patients 
(150 per group) were required to achieve a power of 80% (1-sided 95% CI). 
Assuming a symptom relief rate of 80% for the acute phase, a rate of 90% of 
patients continuing the long-term phase, and 80% of these belonging to the per- 
protocol (PP) population, 520 patients had to be included initially. 
The primary end point in this study was the difference in the estimated rates 
of patients with uncontrolled heartburn, acid regurgitation, and pain on swallow- 
ing between the 2 treatment groups (long-term phase). In each treatment group, 
a survival analysis was performed according to Kaplan-Meier, leading to esti- 
mates of the "survival rate" and its standard error (SE). In these analyses, "sur- 
vival" was associated with "no failure to control all 3 characteristic GERD symp- 
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toms." The difference, "survival rate in the on-demand group minus that in the 
continuous group," and its SE were determined using the Kaplan-Meier results. 
Using these results, the 1-sided 95% CI was calculated. Noninferiority of the on- 
demand treatment with respect o the continuous therapy was concluded if the 
noninferiority margin of 20% was outside of the 1-sided 95% CI. Thus, the null 
hypothesis (that the on-demand therapy is statistically inferior to the continu- 
ous therapy) was tested against he alternative hypothesis (that on-demand is
noninferior). 
The secondary end point for the acute phase was the symptom relief rate, 
together with its 95% binomial confidence limits after 4 weeks of treatment with 
pantoprazole 20 mg. Relief was defined as being free of heartburn, acid regurg- 
itation, and pain on swallowing on the 3 consecutive days before assessment 
and having one or more additional symptoms of at most mild intensity. 
The secondary end point for the long-term phase was the perceived mean daily 
symptom load (time- and medication-weighted symptom load). The mean values of 
both treatment groups were compared using the Wilcoxon rank sum test (1-sided) 
at a 5% ~ level. Thus, the null hypothesis (no difference between treatments) was 
tested versus the alternative hypothesis (that on-demand treatment was statisti- 
cally superior to continuous therapy). In addition, the point estimate of the differ- 
ence between the 2 treatments was determined using the Hodges-Lehman estima- 
tor and the 1-sided 95% CI according to Moses. 2G A 95% CI not including the value 
0 indicated statistical significance. The amount of study medication used was ana- 
lyzed descriptively and compared using the Wilcoxon rank sum test (2-sided). The 
numbers of patients unwilling to continue due to insufficient control of heartburn, 
acid regurgitation, and/or pain on swallowing were analyzed using the Kaplan-Meier 
(time-to-event) analysis. Analysis was done in the same manner as for the primary 
end point, but the 95% CI was interpreted for statistical superiority. In general, 
dichotomous parameters were compared using the Fisher exact est (2-tailed), and 
ordinal variables were compared using the Wilcoxon rank sum test. 
Tablets Used 
The number of pantoprazole tablets used was analyzed by means of descrip- 
tive statistics for the absolute numbers taken over the entire observation period 
and for the mean number of tablets taken per day by each individual during the 
long-term phase. 
Data Sets Analyzed 
Statistical analysis was performed in both the intent-to-treat (ITT) and PP 
populations. Both populations were defined separately in the acute and long- 
term phases, as shown in Figure 1. The ITT population (acute phase) com- 
prised all patients for whom it could not be ruled out that study medication was 
received. In the long-term phase, the ITT population was defined as eligible 
patients for whom it could not be ruled out that study medication was received 
and who attended at least one follow-up visit after starting the long-term phase. 
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The PP analysis excluded protocol violators. The safety population (long-term 
phase) comprised all patients for whom it could not be ruled out that study 
medication was received. 
RESULTS 
Study Population 
A total of 558 patients were enrolled in the study (Figure 1). Four patients did 
not receive study medication, leaving 554 patients in the acute phase ITT popula- 
tion. Fifty-one patients were excluded from the acute phase PP analysis due to 
protocol violations, leaving 503 patients (including 6 withdrawals) in the acute 
phase PP population. The most common protocol violations were loss to follow-up 
(except withdrawals; 23 patients), use of a prohibited concomitant medication 
(19 patients), and deviations from specified follow-up visit dates (8 patients). Pa- 
tients classified as withdrawals in the acute phase withdrew prematurely because 
of an AE (definitely related, 1 patient; likely related, 3; and lack of efficacy, 2). 
After 4 weeks of treatment with pantoprazole 20 mg, 84 patients did not enter 
the long-term phase (55 patients did not have relief of heartburn, acid regurgi- 
tation, and/or pain on swallowing; 23 withdrew during the acute phase [6 due 
to AEs; 6, subsequent violations of inclusion/exclusion criteria; 2, protocol vio- 
lation (poor compliance); 2, lack of efficacy; 7, other reasons]; and 6 discontin- 
ued due to other reasons), leaving 470 patients in the safety population of the 
long-term phase. Thirty-eight of these patients entered the long-term phase 
even though heartburn, acid regurgitation, and/or pain on swallowing were still 
present. Consequently, these patients were classified as ineligible and were 
excluded from the ITT population. The remaining 432 patients were randomized 
to treatment (on-demand, 215 patients; continuous, 217 patients). Ninety-five 
patients were excluded from the PP population because they were classified as 
protocol violators. The most common violations were use of a prohibited con- 
comitant medication (30 patients), loss to follow-up (29 patients), and having 
>10% of diary cards unavailable for evaluation (18 patients). Thus, the PP popula- 
tion comprised 337 patients, 177 (including 2withdrawals) who received on-demand 
therapy and 160 (including 4 withdrawals) who received continuous therapy. 
The 6 patients withdrew prematurely due to lack of efficacy (4 patients) and an 
AEs (2 patients, likely related). 
The demographic characteristics and medical history of the patients in- 
cluded in the ITT population are shown in Table I. No statistically significant 
between-group differences were found. 
Efficacy 
Acute Phase 
After 4 weeks of treatment with pantoprazole 20 mg QD, overall symptom 
relief rates were 79.1% (438/554) and 82.1% (413/503) in the ITT and PP popula- 
tions, respectively. Relief rates of the individual symptoms were 83.3% (449/539) 
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Table I. Baseline demographic and clinical characteristics of the intent-to-treat popu- 
lation of patients receiving pantoprazole 20 mg tablets on-demand or con- 
tinuously for the treatment of mild gastroesophageal reflux disease (GERD) 
(long-term [24-week] phase) (n = 432). 
On-Demand Continuous 
Characteristic (n = 21 S) (n = 217) P 
Age, mean (SD), y 50.4 (13.6) 51.8 (13.5) 0.404 
Sex, no. (%) 0.848 
Female 11S (53.5) 114 (52.5) 
Male 100 (46.5) 1 03 (47.5) 
Body mass index, mean (SD), kg/m 2 26.9 (4.6) 26.6 (4.1) 0.566 
Initial GERD grade,* no. (%) 0.10 
0 48 (22.3) 64 (29.5) ND 
I 167 (77.7) 1 53 (70.5) ND 
ND = not determined. 
*GERD grade according to Savary and Miller, 22 modified by Siewert et al23: grade 0 = normal mucosa; 
grade I = patchy red lesions without white coating or with central white coating. 
for heartburn, 80.0% (403/504) for acid regurgitation, and 91.0% (294/323) for pain 
on swallowing in the ITT population; in the PP population, relief rates were 86.1% 
(422/490) for heartburn, 83.3% (378/454) for acid regurgitation, and 94.2% 
(278/295) for pain on swallowing. For the calculation of symptom relief rates, only 
patients who experienced the respective symptom at baseline were included. The 
numbers of patients with symptoms at baseline varied between symptoms and 
were less than the total number of patients included in the acute phase because 
not all enrolled patients uffered all symptoms (to be eligible for the study, pa- 
tients had to experience only 1 of the 3 characteristic GERD symptoms). 
Long-Term Phase 
Estimated Rate of Patients with Uncontrolled Symptoms 
The effect of both treatment modalities on symptom control, measured as 
the estimated failure rates of patients with uncontrolled heartburn, acid 
regurgitation, and pain on swallowing in each treatment group at the end 
of the long-term therapy, was assessed as the primary end point. In the PP 
population, treatment failed to control symptoms in an estimated 29.5% of 
patients in the on-demand group and an estimated 19.4% of patients in the 
continuous group; thus the between-grnup difference was 10.1%. As the upper 
limit of the 95% CI was 17.7% and, thus, less than the noninferiority margin of 
20%, noninferiority was concluded. This result was similar in the ITT popula- 
tion: in the on-demand group the estimated failure rate was 30.7% compared 
with a rate of 18.6% in the continuous group. Thus, the difference was 12.1%, 
and the upper limit of the 95% CI was 18.9% (Table II). The calculated rates of 
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patients with controlled heartburn, acid regurgitation, and pain on swallowing 
(symptom relief rates using survival time methods fie, 100% minus failure rate]) 
are shown in Figure 2. 
Perceived Mean Daily Symptom Load 
The perceived mean daily symptom loads (ie, the time- and medication- 
weighted symptom loads) are shown in Table III. Patients treated with panto- 
prazole on-demand had a significantly higher GERD symptom load compared 
with patients treated with pantoprazole continuously over 24 weeks (ITT and 
PP, P < 0.001). Consistent with the Wilcoxon test, the point estimate of the dif- 
ference between treatments (on-demand minus continuous using the Hodges- 
Lehman estimator) was 0.38, with a lower confidence limit of 0.26, in the ITT 
population; it was 0.34, with a lower confidence limit of 0.21, in the PP popula- 
tion. Because the value 0 was outside of the 95% CI, the difference was consid- 
ered statistically significant. 
Unwillingness toContinue 
A total of 30 patients in the ITT population (13/215 [6.0%] in the on-demand 
group and 17/217 [7.8%] in the continuous group) discontinued the long-term 
phase prematurely. The rate of premature discontinuation due to insufficient 
symptom control was not statistically significantly different in the on-demand 
group compared with that in the continuous group (the value 0 was within the 
95% CI of the estimated ifference between treatment groups). In the ITT popu- 
lation, the estimated ifference was 0.0% (95% CI, -00% to 1.13%); in the PP pop- 
ulation, the estimated ifference was -0.13% (95% CI, -00% to 1.29%) (Figure 3). 
Table II. Estimated rates of treatment failure* in patients receiving pantoprazole 20 mg 
tablets on-demand or cont inuously for  the t reatment of gastroesophageal 
ref lux disease (GERD) ( long-term [24-week] phase). 
Difference, % 
Population/Parameter On-Demand Continuous (95% CI) 
I1-F 
No. of patients 215 217 - 
Estimated treatment failure rate, % 30.7 18.6 12.1 
95% CI, % 24.5 to 37.0 1 3.4 to 23.8 _0o to 18.9 
PP 
No. of patients 177 1 60 - 
Estimated treatment failure rate, % 29.5 19.4 10.1 
95% CI, % 22.8 to 36.2 1 3.3 to 25.6 _0o to 17.7 
I1-1 = intent-to-treat; PP = per-protocol. 
*Patients in whom treatment failed to control the 3 characteristic symptoms of GERD--heartburn, acid 
regurgitation, and pain on swallowing. 
355 
CURRENT THERAPEUTIC RESEARCH 
Figure 2. 
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Continuous 
Rates of symptom relief (controlled heartburn, acid regurgitation, and pain 
on swallowing) in patients receiving pantoprazole 20 mg tablets for the 
treatment of gastroesophageal reflux disease (long-term [24-week] phase). 
ITT = intent-to-treat population; PP = per-protocol population. No signifi- 
cant between-group differences were found. 
Table III. Perceived mean daily symptom load (MDSL)* in patients receiving panto- 
prazole 20 mg tablets on-demand or continuously for the treatment of gas- 
troesophageal reflux disease (long-term [24-week] phase). 
Difference, %t 
Population/Parameter On-Demand Continuous (95% CI) P 
Ilq- 
No. of patients 212~ 21 7 - - 
MDSL, mean (SD) 1.26 (1.49) 0.82 (1.34) 0.38 <0.001 
(0.26-~o) 
PP 
No. of patients 1 77 1 60 - - 
MDSL, mean (SD) 1.15 (1.33) 0.90 (1.47) 0.34 <0.001 
(0.21-oo) 
ITI- = intent-to-treat; PP = per-protocol. 
*See text for method of calculation. 
tpoint estimate of the difference between treatments (on-demand minus continuous using the Hodges- 
Lehman estimator). 
~Data were unavailable in 3 patients. 
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Tolerabil ity 
Tolerability data were analyzed in the ITT population in the acute phase (n = 
554) and in the safety population in the long-term phase (n = 470) (Table IV). 
One of 87 (1%) AEs (gastrointestinal disorder) in the acute phase was consid- 
ered definitely related to pantoprazole use; none of the AEs in the long-term 
phase were considered efinitely related to treatment. The most common AE 
symptoms in the long-term phase were bronchitis (on-demand: 6 AE symptoms, 
2% of patients; continuous: 9 AE symptoms, 3% of patients), lumbar pain (on- 
demand: 5 AE symptoms, 2% of patients; continuous: 6 AE symptoms, 2% of 
patients), and cervicobrachialgia (on-demand: 4 AE symptoms, 2% of patients; 
continuous: 5AE symptoms, 2% of patients). In the long-term phase, none of the 
serious AEs were considered to be related to the study medication. No statisti- 
cally significant differences in the safety profile between the on-demand and 
continuous groups were found. 
Tablets Used 
Both the absolute and mean number of tablets taken per day were signifi- 
cantly lower in the on-demand group compared with the continuous group (ITT 
and PP, P < 0.001) (Table V). 
1.13  
• 113- 
DPP 
~v,  1.5 
e~ e- 
om 
~ 1.0 
o.s 
1.26  
(n -- 21S) (n  -- 177) 
On-Demand 
2.0 
T I 
(n = 21Z)(n = 160) 
Continuous 
Figure 3. Estimated rates of patients unwilling to continue treatment due to inade- 
quate symptom control (long-term phase) (analyzed using the Kaplan- 
Meier method in the intent-to-treat [ITT] and the per-protocol [PP] popula- 
tions). No significant between-group differences were found. 
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Table IV. Adverse events (AEs) in patients receiving pantoprazole 20 mg tablets for 
the treatment of gastroesophageal reflux disease.* 
Parameter 
Long-Term (24-wk) 
Phase (Safety) Acute (4-wk) 
Phase (I- I-F) On-Demand Continuous 
(n = 554) (n = 234) (n = 236) 
No. (%) of patients with AEs t 64 (12) 70 (30) 88 (37) 
No. of AE symptoms 87 149 1 78 
Most common AE symptoms, 
no. of symptoms (% of patients) 
Bronchitis 0 6 (2) 9 (3) 
Lumbar pain 4 (<1) 5 (2) 6 (2) 
Cervicobrachialgia 0 4 (2) 5 (2) 
Influenza-like symptoms 4 (<1) 0 0 
Exanthema 3 (<1) 0 0 
Relation to treatment, no. (%) of AEs 
Unrelated 62 (71) 11 5 (77) 1 51 (85) 
Not likely related 1 6 (18) 25 (1 7) 20 (11 ) 
Likely related 8 (9) 9 (6) 7 (4) 
Definitely related 1 (1) 0 0 
Intensity, no. (%) of AEs 
Mild 35 (40) 62 (42) 77 (43) 
Moderate 41 (47) 71 (48) 81 (46) 
Severe 11 (13) 1 6 (11 ) 20 (11 ) 
Serious AEs,* 
no. of symptoms (% of patients) 4 (<1) 6 (3) 14 (6) 
AEs leading to withdrawal, 
no. of symptoms (% of patients) 6 (1) 5 (2) 11 (5) 
ITI- = intent-to-treat. 
*No sig nifica nt between-grou p differences were found. 
tSome patients experienced >1 AE. 
*None of the serious AEs were treatment related. 
DISCUSSION 
This study was designed to compare the control of GERD symptoms during long- 
term treatment with pantoprazole 20 mg used on-demand versus continuously in
patients with mild GERD after acute relief of heartburn, acid regurgitation, and 
pain on swallowing. A recent study of pantoprazole 20 mg in 1552 patients with 
mild GERD showed that only 40.3% of patients used their medication as pre- 
scribed (once daily); noncompliers used it 2 to 6 d/wk (intermittent). 27 This find- 
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Table V. Pantoprazole 20 mg tablets used* per patient on-demand or continuously 
for the treatment of gastroesophageal reflux disease (long-term [24-week]  
phase). Values are presented as mean (SD). 
Population/Parameter On-Demand Continuous P 
117- 
No. of patients 215 21 7 - 
Daily 0.51 (0.31) 0.93 (0.1 7) <0.001 
Total 83.2 (52.4) 1 52.4 (38.2) <0.001 
PP 
No. of patients 1 77 160 - 
Daily 0.51 (0.31) 0.97 (0.11) <0.001 
Total 84.3 (51.4) 1 61.8 (27.3) <0.001 
117- = intent-to-treat; PP = per-protocol. 
*Analyzed using descriptive statistics for the absolute number of tablets used over the entire observa- 
tion period and for the mean number of tablets used per day by each individual. 
ing suggests that on-demand use of medication i the long term matches patients' 
self-medication behavior. Preliminary data from a 1-year study of on-demand ver- 
sus continuous use of pantoprazole in 100 patients with mild GERD showed that 
both treatment modalities were similarly tolerable, although the frequency of 
symptomatic reflux episodes was significantly increased from baseline in the on- 
demand group after 3 months. 2~ Based on our literature search, data from a direct 
comparison of on-demand and continuous use of pantoprazole in a large clinical 
setting have not been fully published to date. 
The primary end point of the present study was the estimated rate of 
patients with uncontrolled heartburn, acid regurgitation, and pain on swallow- 
ing in the long-term phase. During this phase, on-demand treatment with panto- 
prazole 20 mg was compared irectly with continuous treatment with pantopra- 
zole. The comparison of the 2 treatment groups by means of a noninferiority 
test was chosen as the primary end point because although it was anticipated 
that on-demand therapy would be statistically inferior to continuous therapy in 
controlling GERD symptoms, we attempted to show that patients would toler- 
ate a certain level of symptoms but would medicate themselves when the symp- 
toms became sufficiently severe. On-demand therapy implies that the patients 
experience at least mild GERD symptoms for a short period before they begin 
using tablets. This period could vary greatly due to different on-demand habits 
of the study patients. Indeed, 12.1% more patients in the on-demand group than 
the continuous group failed to control their symptoms. However, on-demand 
treatment was shown to be noninferior to continuous treatment. 
To obtain data comparable to that in 2 studies of pantoprazole, 2° 21 the per- 
ceived mean daily symptom load was assessed in both groups. We used this as 
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an additional efficacy end point because symptom load was considered the 
most appropriate model of the clinically relevant question of symptom control 
in long-term treatment of GERD. In the literature, some authors recommend 
unwillingness to continue as a measurement of the efficacy of on-demand treat- 
ment. 2-4 However, this parameter is only an indirect measure of the control of 
GERD symptoms and reflects one point in time in patients who discontinued 
treatment, hereby assessing only a subset of patients. Patients treated with 
pantoprazole on-demand had a significantly higher perceived mean daily symp- 
tom load compared with patients treated with pantoprazole continuously over 
24 weeks. This finding is not surprising and was anticipated because in contrast 
to patients assigned to receive continuous therapy, patients in the on-demand 
group were instructed to use the study medication only when their symptoms 
required treatment. Again, it could be assumed that patients did not use tablets until 
they experienced a short period of at least mild symptoms, and self-medication 
habits can vary greatly from patient o patient. 
The main outcome of this study was further supported by the rate of patients 
unwilling to continue the study, a variable often used in studies of other PPIs. The 
rate of premature discontinuation due to insufficient control of heartburn, acid 
regurgitation, and pain on swallowing was not significantly different in the on- 
demand group compared with that in the continuous group. This result suggests 
that patients felt sufficiently treated regardless of their treatment regimen, 
although the symptom load was significantly higher in the on-demand group. 
However, the symptom load in the on-demand group might have been higher 
compared with the continuous group because symptoms must develop for a 
patient o use the study medication. It is possible that many patients in the on- 
demand group continued treatment despite a higher symptom load because on- 
demand treatment might confer an increased sense of control. Results from a 
study comparing continuous esomeprazole 20mg with on-demand esomeprazole 
40 mg showed that both regimens provided similar rates of patient satisfaction 
(89.6% and 88.4%, respectively). 29 In the present study, the similarity of the rates 
of patients willing to continue treatment between the 2 groups might suggest that 
on-demand treatment is noninferior to continuous treatment with regard to 
patients' perceptions of treatment. In previous work, discontinuation rates were 
14% with omeprazole 20 mg, 2 and 5% to 14% with esomeprazole 20 mg3,4,7; the 
rates of patients unwilling to continue on-demand therapy of 6-month duration 
were 11% with esomeprazole 40mg, 4 15% with lansoprazole 15 mg, 8 and 6% with 
rabeprazole 10 mg. 1° 
The amount of medication used in the on-demand group was nearly half that 
in the continuous group; the difference was statistically significant. These find- 
ings verify that patients' dosing habits were based on as-needed ecisions and 
that on-demand therapy can be clearly distinguished from continuous therapy. 
Our findings were also comparable to those from previous tudies of on-demand 
treatment. In one study of 6 months of on-demand therapy, the mean numbers of 
tablets used per day were 0.43 with omeprazole 20 mg, 2 0.33 with esomeprazole 
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20 mg, 4 and 0.40 with lansoprazole 15 mg. ~ Due to the reduced number of tablets 
received (less than half the amount with daily use), on-demand treatment has the 
potential to be more cost-effective compared with continuous treatment. 16
CONCLUSIONS 
In this study of pantoprazole 20 mg tablets in patients with mild GERD, pa- 
t ients receiving on-demand treatment benefited espite their  higher symptom 
load. The similar rates of unwillingness to continue treatment between the 
2 groups might suggest hat patients were satisfied with the on-demand treat- 
ment strategy. On-demand treatment with pantoprazole 20 mg was found to be 
noninferior compared with cont inuous therapy with regard to symptom con- 
trol. Both on-demand and cont inuous t reatments were well tolerated. 
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